Event:	Central Nervous System Disease Conference
Date/Time:	Thursday, November 17, 2016
Location:	Maxim Group LLC, New York, NY

Related Posts

Anavex Life Sciences Announces First Participant Enrolled in Phase 1 Study of ANAVEX®3-71 (AF710B)
July 6, 2020

Anavex Life Sciences Announces First Patient Dosed in EXCELLENCE Phase 2/3 Clinical Trial of ANAVEX®2-73 (Blarcamesine) in Patients with Rett Syndrome
July 1, 2020

Anavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) U.S. Phase 2 Rett Syndrome Clinical Trial
June 16, 2020

Anavex Life Sciences Receives Regulatory Approval from Health Canada and UK MHRA Expanding Phase 2b/3 ANAVEX®2-73 (blarcamesine) into Multinational Clinical Trial for Alzheimer’s Disease
June 4, 2020